论文部分内容阅读
目的:制备血管内皮生长因子受体Ⅱ(VEGFRⅡ)介导的靶向六氟化硫微泡显像剂,并评价其对乳腺癌细胞MCF-7的靶向性。方法:采用薄膜分散-超声法制备六氟化硫微泡显像剂,以粒径分布为评价指标,通过Box-Behnken效应面法优化六氟化硫微泡显像剂的处方,采用吸附法制备VEGFRⅡ介导靶向微泡显像剂,并对VEGFRⅡ介导靶向微泡显像剂的表观形态、粒径分布、Zeta电位进行表征;用免疫荧光法检测VEGFRⅡ介导靶向微泡显像剂的靶向作用。结果:VEGFRⅡ介导靶向微泡显像剂的平均粒径为(3.81±0.32)μm,多聚分散系数为0.261±0.037,Zeta电位为(-25.7±2.8)m V;透射电镜观察其大小比较均匀,呈规则球形或类球形分布;免疫荧光实验结果显示VEGFRⅡ介导靶向微泡显像剂在体外能与乳腺癌细胞MCF-7特异性结合。结论:通过吸附法可成功制备VEGFRⅡ介导靶向微泡显像剂,在体外具有较强的寻靶能力。
OBJECTIVE: To prepare vascular endothelial growth factor receptor Ⅱ (VEGFRⅡ) -mediated targeted SF6 microbubble imaging agent and evaluate its targeting to breast cancer cells MCF-7. Methods: SF6 microbubbles imaging agent was prepared by thin-film dispersion-ultrasound method. The particle size distribution was used as evaluation index to optimize the formulation of SF6 microbubble imaging agent by Box-Behnken effect surface method. The VEGFRⅡ-mediated targeted microbubble imaging agent was prepared and the apparent morphology, particle size distribution and Zeta potential of VEGFRⅡ-mediated targeted microbubble imaging agent were characterized. Immunofluorescence assay was used to detect the effect of VEGFRⅡ- Targeted imaging agent. Results: The average particle size of VEGFRⅡ-mediated microbubble imaging agent was (3.81 ± 0.32) μm, the polydispersity was 0.261 ± 0.037 and the zeta potential was (-25.7 ± 2.8) mV. The size of VEGFRⅡ- The results showed that VEGFRⅡmediated targeted microbubble imaging agent could specifically bind to breast cancer cell MCF-7 in vitro. Conclusion: VEGFRⅡ-mediated targeted microbubble imaging agent can be successfully prepared by adsorption method and has strong targeting ability in vitro.